BIC4VMR: Breakthrough Improvement Collaborative for Ventral Mesh Rectopexy
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- KU Leuven
- 入组人数
- 320
- 试验地点
- 1
- 主要终点
- Length of stay
研究概览
简要总结
Different studies showed large variation between care processes in multiple diseases, this leads to large variation in outcomes. Better adherence to evidence-based guidelines for these diseases can reduce this variation and can improve the health outcomes.
Ventral mesh rectopexy has gained popularity in Europe to treat different rectal prolapse syndromes. This procedure has been shown to achieve acceptable anatomic results with low recurrence rates, few complications, and improvements of both constipation and fecal incontinence. However, there is limited data on the care process and outcomes. Moreover, there is no insight in the variation between different centers for patients undergoing ventral mesh rectopexy.
This study aims to map the variation in care for patients undergoing ventral mesh rectopexy in Flemish hospitals and to get an overview about the variation within and between these hospitals. Hereby, this will be a repeat of the studies for colorectal cancer, fragility hip fractures, stroke and breast cancer surgery.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Minimum age of 18 years;
- •Elective admission for ventral mesh rectopexy
- •Total rectal prolapse
- •Grade III Internal prolapse with incontinence or obstructed defaecation
排除标准
- •Colpo posterior
- •Patients diagnosed with severe dementia (DSM IV) or severe concomitant disease that may affect very short-term outcome (life expectancy less than 3 months) and hence influence deviations from standard acute care.
结局指标
主要结局
Length of stay
时间窗: through study completion, an average of 4 months
Number of days in the hospital
次要结局
- 30 days mortality rate(through study completion, an average of 4 months)
- In-hospital complication rate(through study completion, an average of 4 months)
- in-hospital mortality(through study completion, an average of 4 months)
- 30 day readmission rate(through study completion, an average of 4 months)